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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastroin-
testinal malignant disease, with an estimated overall 5-year 
survival rate of less than 5%. While the most effective treatment 
option is margin-negative pancreatectomy, only about 15–20% 
of patients with a new diagnosis of PDAC can undergo surgi-
cal resection, and their 5-year survival rate is around 20%.1 
Most PDAC patients experience recurrence and cancer-relat-
ed mortality.
In investigating the biologic behavior of PDAC, cancer-relat-
ed factors and host-related factors need to be considered. Sev-
eral cancer-related factors, such as margin status, tumor size, 
tumor (T) stage, nodal (N) stage, tumor differentiation, lym-
phovascular invasion, perineural invasion, major vascular in-
vasion, and high levels of preoperative or postoperative CA19-9, 
have been identified as important cancer-related prognostic 
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factors.1 Host-related factors, for example, physical activity2 and 
host immune responses to cancer, have also been reported to 
be important in determining the disease-related prognosis for 
a variety of cancers.3-6 Because tumor infiltrating lymphocytes 
(TILs) are thought to reflect the host immune response against 
tumors, TILs are considered prognostic factors.7-10 
Tumor infiltrating CD8+ cytotoxic T lymphocytes and CD4+ 
helper T lymphocytes act as antitumor effectors and are asso-
ciated with a favorable outcome.11 Activated CD8+ T-cells at-
tack tumor cells presenting tumor associated antigens via the 
peptide/major histocompatibility complex class I on the tumor 
cell surfaces.12 Activated CD8+ T-cell express granzyme B on 
their surface.13 Unlike CD4+ and CD8+ T-cells, regulatory T 
lymphocytes (Treg) have been shown to have an adverse ef-
fect on the prognosis of patients by suppressing effector T-cells 
and the production of several immunosuppressive cytokines, 
including interleukin-10 and transforming growth factor-β.14 
The forkhead/winged helix transcription factor, forkhead P3 
(Foxp3), which is genetically defective in autoimmune and in-
flammatory syndromes in humans and mice, is specifically ex-
pressed in naturally arising CD4+ Tregs.15 In our previous study 
of the prognostic impact of TILs in resected left-sided PDAC,16 
we demonstrated that a low tumor infiltrating Foxp3+/gran-
zyme B+ ratio was an independent factor predicting good dis-
ease-free survival (DFS) and overall survival (OS) outcomes. 
We have been performing minimally invasive radical pan-
createctomies in well-selected left-sided PDAC.17-19 In doing so, 
we have applied the Yonsei criteria for patient selection based 
on preoperative CT scans and included the following tumor 
conditions: 1) tumor confined to the pancreas, 2) intact fascia 
layer between the distal pancreas and the left adrenal gland 
and kidney, and 3) tumor located more than 1–2 cm from the 
celiac axis. With our selection criteria, minimally invasive radi-
cal pancreatectomy was both feasible and oncologically safe.17-19 
In our recent study evaluating the long-term oncologic out-
comes of minimally invasive radical distal pancreatectomy for 
left-sided PDAC,19 we noted that when patients satisfied the 
Yonsei criteria, they experienced longer long-term survival, 
regardless of surgical approach (open vs. minimally invasive 
surgery), suggesting that the Yonsei criteria may play some role 
in the prediction of tumor aggressiveness for resected left-sid-
ed PDAC.
 In this study, we investigated the impact of TIL subsets on 
patient survival outcomes and whether the Yonsei criteria 
predicted a favorable tumor microenvironment characterized 
by the distribution of TILs. We suggest that the Yonsei criteria 
may both serve as patient selection criteria for cancer treat-
ment and reflect a favorable host immunologic microenviron-
ment in left-sided PDAC.
MATERIALS AND METHODS
Patients 
Patients who underwent curative distal pancreatectomy due 
to left-sided PDAC from January 2000 to December 2011 at 
Severance Hospital, Yonsei University College of Medicine 
(Seoul, Korea) were enrolled. Patients with pancreatic head 
cancer were excluded to avoid potential contamination with 
other periampullary cancers, such as distal bile duct, ampulla 
of Vater, and duodenal cancers. We retrospectively analyzed 
patient demographics, histopathologic findings, and survival 
outcomes. Follow-up was completed September 30, 2015. Pa-
tients who received neoadjuvant chemotherapy or chemora-
diation therapy and had other primary tumors were exclud-
ed.16 OS was defined as the interval between surgery and death 
or between surgery and the last observation for surviving pa-
tients. DFS was defined as the interval between surgery and re-
currence. This study was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University College of Med-
icine (4-2013-0264).
Immunohistochemical staining and quantification of 
TIL subsets
Immunohistochemical (IHC) staining for TIL subsets was per-
formed as previously described.5,16 Briefly, paraffin-embed-
ded PDAC tissue sections at a thickness of 4 µm were deparaf-
finized in xylene and rehydrated in decreasing concentrations 
of ethanol. Antigen retrieval was performed in citrate buffer in a 
microwave oven. Endogenous peroxidase activity was blocked 
by incubating the tissue with 3% hydrogen peroxide in metha-
nol for 5 min. The sections were incubated for 60 min at room 
temperature with primary monoclonal antibodies against clus-
ter of differentiation (CD)3 (Cat. No. RM-9107-S, 1:100, Lab 
Vision Corporation, Fremont, CA, USA), CD4 (Cat. No. NCL-
L-CD4-1F6, 1:100, NovocastraTM, Newcastle upon Tyne, UK), 
CD8 (Cat. No. IS62330, 1:100, Dako, Glostrup, Denmark), 
Foxp3 (Cat. No. ab20034, 1:100, Abcam, Cambridge, UK), and 
granzyme B (Cat. No. MS-1157-S, 1:100, Lab Vision Corpora-
tion), which were used to identify total numbers of T-cells, help-
er T-cells, cytotoxic T-cells, Treg, and activated cytotoxic T-cells, 
respectively. After washing the sections twice with 0.05 mol/L 
Tris-buffered saline with 0.2% Tween-20, the sections were 
incubated with horseradish peroxidase-conjugated secondary 
antibody (Dako EnVision® Detection system, Dako), followed 
by development with diaminobenzidine and counterstaining 
with hematoxylin (Fig. 1). 
IHC staining was quantified by two experienced pathologists 
who were blinded to patient data. Three intense foci of staining 
in the tumor sections were selected and four high-power fields 
(magnification, ×400) from each slide were selected for calcu-
lation of IHC staining results. TILs tended to be distributed more 
in the interstitial area of the tumor microenvironment.16 Fields 
with necrosis or hemorrhage in the tumor portion were avoid-
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ed.5,16 Patients were divided into low and high groups using the 
median value of absolute counts for positively stained cells and 
relative ratios between Treg and T-cells (CD3+, CD4+, CD8+, and 
granzyme B+ T-cell). 
Statistical analysis
All statistical analyses were performed with SPSS 20.0 soft-
ware (IBM, Corp., Armonk, NY, USA). Categorical variables 
were compared using χ2 or Fisher exact tests. Absolute counts 
of TIL subsets and the relative ratio between Treg and T-cells 
(CD3+, CD4+, CD8+, and granzyme B+ T-cells) were divided 
into two groups using cut-off values derived from the median 
value for χ2 or Fisher exact tests and survival analysis.5,9,16 OS 
and DFS were calculated using the Kaplan-Meier method, and 
significance was evaluated by the log-rank test. Cox propor-
tional hazard models were used for univariate and multivari-
ate survival analysis. A p-value of 0.05 or less indicated statisti-
cal significance.
RESULTS
Patient demographics and general characteristics of 
resected left-sided PDAC
A total of 72 patients underwent curative distal pancreatecto-
my for left-sided PDAC. Among them, 13 patients who under-
went neoadjuvant chemoradiation therapy were excluded. 
Nine patients were excluded because a paraffin-embedded tis-
sue block was not available. Finally, 50 patients were enrolled 
in this study. The mean age was 62.8±9.4 years, and 20 patients 
(40%) were female. Only 3 patients (6%) underwent minimally 
invasive (laparoscopic or robotic) distal pancreatectomy. The 
mean operation time was 290±167 min. Combined organ re-
section was performed in 12 patients (24%). Thirteen patients 
(26%) received intraoperative transfusion. No postoperative 
mortality or severe complications (Clavien-Dindo classification≥ 
IIIa) were recorded. The mean tumor size was 3.5±1.5 cm. Path-
ological T staging revealed T1 in 1 (2%), T2 in 5 (10%), T3 in 42 
(84%), and T4 in 2 patients (4%). Pathologic N1 stage was ob-
served in 23 patients (46%). Lymphovascular invasion and 
perineural invasion were observed in 10 patients (20%) and 23 
patients (46%), respectively. Tumor differentiation was classi-
fied into one of four groups: 11 well differentiated, 34 moder-
ately differentiated, four poorly differentiated, and one un-dif-
ferentiated. Resection margin status was R0 in 45 (90%), R1 in 
3 (6%), and R2 in 2 (4%) patients. All patients received postop-
erative adjuvant chemotherapy with gemcitabine.
Survival analysis according to clinicopathologic and 
operative findings
Survival outcomes based on univariate and multivariate anal-
yses according to clinicopathologic parameters and operative 
findings are shown in Table 1. Univariate analysis showed pa-
tients satisfying Yonsei criteria (p=0.021), with fewer than two 
metastatic lymph nodes (LNs) (p<0.001), without combined 







Fig. 1. Hematoxylin and eosin, and IHC staining for tumor-infiltrating T lymphocytes. Hematoxylin and eosin staining from paraffin blocks (A) was per-
formed to confirm tissue quality. IHC detection of CD3+ T lymphocytes (B), CD4+ helper T lymphocytes (C), CD8+ cytotoxic T lymphocytes (D), Foxp3+ regu-
latory T lymphocytes (E), and granzyme B+ activated cytotoxic T lymphocytes (F) in consecutive sections is shown (original magnification, ×400). IHC, im-
munohistochemical.
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sion (p=0.005) were associated with longer DFS. Univariate 
analysis also showed small tumor size (<3.5 cm, p=0.031), sat-
isfying Yonsei criteria (p=0.001), fewer than two metastatic LNs 
(p=0.003), no combined organ resection (p=0.008) and no in-
traoperative transfusion (p=0.028) to be associated with longer 
OS. Multivariate analysis demonstrated that having more than 
two metastatic LNs [Exp(β)=3.354; 95% confidence internal (CI): 
1.582–7.110; p=0.002] and intraoperative transfusion [Exp(β)= 
2.615; 95% CI: 1.248–5.482; p=0.011] to be independent risk fac-
tors for DFS. Not satisfying Yonsei criteria [Exp(β)=2.590; 95% 
CI: 1.151–5.829; p=0.021] and more than two metastatic LNs 
[Exp(β)=2.536; 95% CI: 1.083–5.936; p=0.032] were indepen-
dent risk factors for OS (Table 1).
Survival analysis according to TIL subsets
Univariate analysis showed that high CD8+ levels were signifi-
cantly related to longer DFS (p=0.002) and OS (p=0.016). High 
granzyme B+ levels were significantly associated with longer 
DFS (p=0.033). Low levels of Foxp3+/CD4+, Foxp3+/CD8+, and 
Foxp3+/granzyme B+ were favorable prognostic factors in DFS 
(p=0.041, p=0.005, and p=0.014, respectively) and OS (p=0.034, 
p=0.012, and p=0.040, respectively) (Table 2). The Cox regres-
sion hazards model demonstrated that low levels of CD8+ [Exp 
(β)=3.436; 95% CI: 1.701–6.944; p=0.001] and high Foxp3+/CD8+ 
Table 1. Survival Analysis According to Clinicopathologic and Operative Findings
DFS OS
Univariate Multivariate Univariate Multivariate
Months p value Exp(β) 95% CI p value Months p value Exp(β) 95% CI p value
Age, yr  
 <63 (n=25)/≥63 (n=25) 13.7/11.1 0.333 28.6/33.2 0.982
Sex
Male (n=30)/Female (n=20) 12.5/10.3 0.915 33.2/27.9 0.765
CA19-9, U/mL
≤109 (n=24)/>109 (n=25) 18.0/10.2 0.243 35.8/21.7 0.340
Tumor size, cm
<3.5 (n=27)/≥3.5 (n=23) 13.7/8.4 0.134 42.1/18.9 0.031
Yonsei criteria 0.021 0.001
Satisfying (n=23) 23.6  65.7 
Not satisfying (n=27) 10.3 20.2 2.590 1.151–5.829 0.021
NCCN resectability
 Resectable (n=44)/Borderline (n=6) 12.5/10.2 0.475 28.6/65.7 0.330
pN stage
N0 (n=27)/N1 (n=23) 13.7/10.2 0.094 37.2/21.2 0.143
Number of metastatic LNs <0.001 0.003
<2 (n=36) 15.1 
≥2 (n=11)   7.9 3.354 1.582–7.110 0.002 37.2 2.536 1.083–5.936 0.032
LN ratio in N1 stage 18.9
<0.09 (n=11)/> 0.09 (n=12) 13.5/4.6 0.352 22.0/18.9 0.623
Combined organ resection
No (n=38)/Yes (n=12) 13.7/7.27 0.020 37.2/13.3 0.008
Differentiation 0.213 0.401
Well (n=11) 18.7 42.1
Moderate (n=34) 12.5 28.6
Poor (n=4)   3.2 13.3
Undifferentiation (n=1)   8.0 39.3
Lymphovascular invasion
No (n=37)/Yes (n=10) 12.2/18.0 0.676 28.6/21.2 0.865
Perineural invasion
No (n=24)/Yes (n=23) 12.2/12.8 0.849 22.0/33.2 0.444
Transfusion 0.005 0.028
No (n=37) 18.0 39.3 �
Yes (n=13)   6.6 2.615 1.248– 5.482 0.011 20.28
DFS, disease-free survival; OS, overall survival; CI, confidence interval; NCCN, National Comprehensive Cancer Network; LNs, lymph nodes.
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ratios [Exp(β)=2.505; 95% CI: 1.262–4.974; p=0.009] were inde-
pendent prognostic factors for recurrence of resected left-sided 
PDAC. Low levels of CD8+ [Exp(β)=2.140; 95% CI: 1.035–4.426; 
p=0.040] and high levels of Foxp3+/CD8+ [Exp(β)=2.235; 95% 
CI: 1.074–4.650; p=0.032] were also independent prognostic 
factors for unfavorable OS (Table 2, Figs. 2 and 3).
Association between clinicopathologic factors and 
CD8+ counts and Foxp3+/CD8+ ratio
Among the preoperatively determined clinical factors used to 
predict patient survival, high levels of CA19-9 (p=0.022) and not 
satisfying Yonsei criteria (p=0.022) were significantly associat-
ed with a high Foxp3+/CD8+ ratio. Age, tumor size, gender, and 
NCCN resectability were not associated with CD8+ levels or 
Foxp3+/CD8+ ratio. Among the postoperative pathologic fac-
tors, more than two metastatic LNs were related with low tu-
mor infiltrating CD8+ levels (p=0.020) and a high Foxp3+/CD8+ 
ratio (p=0.049). Mean LN ratios (LNR, the ratio of metastatic to 
retrieved LNs) were significantly higher in the high Foxp3+/CD8+ 
group (p=0.020). Pathologic tumor stage, nodal stage, tumor 
differentiation, lymphovascular invasion, and perineural inva-
sion were not associated with CD8+ levels or Foxp3+/CD8+ ratio 
(Table 3). In multivariate analysis, high levels of CA19-9 and 
not satisfying Yonsei criteria were significantly associated with 
a high Foxp3+/CD8+ ratio [Exp(β)=3.558; 95% CI: 1.000–12.658; 
p=0.050] (Table 4). When the two factors, Yonsei criteria and 
CA19-9, were combined for analysis of factors affecting the 
CD8+ counts and Foxp3+/CD8+ ratio, high levels of CA19-9 and 
not satisfying Yonsei criteria were significantly associated with a 
high Foxp3+/CD8+ ratio, compared to other conditions (p=0.024) 
(Table 5).
DISCUSSION
In this study, we investigated the effects of TILs on the prog-
Table 2. Survival Analysis According to Tumor Infiltrating Lymphocyte Counts
DFS OS
Univariate Multivariate Univariate Multivariate
Months p value Exp(β) 95% CI p value Months p value Exp(β) 95% CI p value
Absolute count (stained cell number)
CD3+ 0.918 0.724
Low (≤265, n=24) 12.5 35.8
High (>265, n=26) 11.1 27.9
CD4+ 0.594 0.903
Low (≤143, n=25) 11.1 29.7
High (>143, n=25) 13.7 33.2
CD8+ 0.002 0.016
Low (≤121, n=25)   8.4 3.436 1.701–6.944 0.001 18.9 2.140 1.035–4.426 0.040
High (>121, n=25) 18.7 43.7
Granzyme B+ 0.033 0.136
Low (≤24, n=24) 10.2 29.9
High (>24, n=26) 18.0 37.2
Foxp3+ 0.435 0.368
Low (≤25, n=25) 13.5 39.3
High (>25, n=25) 10.3 27.9
Relative ratio
Foxp3+/CD3+ 0.151 0.296
Low (≤0.11, n=26) 15.1 39.3
High (>0.10, n=24) 10.2 23.9
Foxp3+/CD4+ 0.041 0.034
Low (≤0.17, n=25) 15.1 48.3
High (>0.17, n=25) 10.2 21.3
Foxp3+/CD8+ 0.005 0.012
Low (≤0.23, n=26) 18.7 48.3
High (>0.23, n=24)   9.4 2.505 1.262–4.974 0.009 21.2 2.235 1.074–4.650 0.032
Foxp3+/Granzyme B+ 0.014 0.040
Low (≤0.17, n=25) 18.7 39.3
High (>0.17, n=25)   9.4 20.2
DFS, disease-free survival; OS, overall survival; CI, confidence interval.
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nosis of left-sided PDAC and examined whether the Yonsei 
criteria were associated with differences in TIL distributions. 
In addition to clinicopathologic factors, the host immune re-
sponse against tumors plays a critical role in survival outcomes 
for numerous types of cancers.3-5,8,10,11 In terms of TIL subsets, a 
ratio of low Treg density to high T-cells (CD4+, CD8+, and gran-
zyme B+ T-cell) has been reported to be a promising indepen-
dent favorable factor in various tumors.4,5,9 In our previous 
study,16 we showed that patients with a low Foxp3+/granzyme B+ 
ratio had significantly improved DFS (25 months vs. 8 months; 
p=0.008) and OS (47 months vs. 17 months; p=0.003). Multi-
variate analysis of the data accumulated since our previous 
study supports that a high level of CD8+ cells and a low Foxp3+/
CD8+ ratio are independent predictors for favorable DFS 
(p=0.001 and p= 0.009, respectively) and OS (p=0.040 and 
p=0.032, respectively) (Table 2, Figs. 2 and 3). 
In our previous study, we analyzed clinicopathologic factors 
associated with differences in the distribution of TIL subsets: 
only low levels of CA19-9 were significantly associated with a 
low Foxp3+/granzyme B+ ratio. Even though several studies have 
demonstrated that distributions of TILs are associated with 
survival outcomes in patients with PDAC,20-22 only a few stud-
ies have described clinicopathologic factors associated with 
differences in TILs distribution. Fukunaga, et al.20 reported that 
positivity for both tumor infiltrating CD4+ T-cells and CD8+ T-
cells was significantly associated with a lower grade of depth 
of invasion and tumor stage, compared with both negative 
group. Hiraoka, et al.23 demonstrated that a high prevalence of 
Treg in CD4+ T-cells was significantly correlated with distant 
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Fig. 2. Kaplan-Meier analysis of DFS (A) and OS (B) according to CD8+ levels (low vs. high; number of cells stained with immunohistochemical stain-
ing). The group with high levels of CD8+ showed favorable survival outcomes in regards to DFS (p=0.001) and OS (p=0.040). DFS, disease-free survival; 
OS, overall survival.
Fig. 3. Kaplan-Meier analysis of DFS (A) and OS (B) according to Foxp3+/CD8+ ratio (low vs. high). Low Foxp3+/CD8+ ratio showed favorable survival 
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These studies have investigated pathologic findings that could 
only be analyzed postoperatively. To our knowledge, there are 
no other studies that have analyzed preoperative clinical fac-
tors associated with TILs to predict patient survival outcomes. 
In the present study, among the preoperatively detected clini-
cal factors, high levels of CA19-9 (p=0.022) and not satisfying 













Age, yr 1.000 >0.999
<63 13 (52) 12 (48) 13 (50) 12 (50)
≥63 12 (48) 13 (52) 13 (50) 12 (50)
Gender 0.387 0.729
Male 13 (52) 17 (68) 15 (57.7) 15 (62.5)
Female 12 (48) 8 (32) 11 (42.3) 9 (37.5)
Tumor size, cm 0.256 0.586
<3.5 11 (44) 16 (64) 15 (57.7) 12 (50)
≥3.5 14 (56) 9 (36) 11 (42.3) 12 (50)
CA19-9, U/mL 0.778 0.022
<109 11 (45.8) 13 (52) 17 (65.4) 7 (30.4)
≥109 13 (54.2) 12 (48) 9 (34.6) 16 (69.6)
Yonsei criteria 0.777 0.022
Satisfying 11 (44) 12 (48) 16 (61.5) 7 (29.2)
Not satisfying 14 (56) 13 (52) 10 (38.50 17 (70.8)
NCCN resectability 0.667 >0.999
Resectable 21 (84) 23 (92) 23 (88.5) 21 (87.5)
Borderline 4 (16) 2 (8) 3 (11.5) 3 (12.5)
Pathologic factors
pT stage 0.187 0.164
T1 0� 1 (4) 1 (3.8) 0�
T2 4 (16) 1 (4) 4 (15.4) 1 (4.2)
T3 21 (84) 21 (84) 19 (73.1) 23 (95.8)
T4 0� 2 (8) 2 (7.7) 0�
pN stage 0.571 0.093
N0 12 (48) 15 (60) 17 (65.4) 10 (41.7)
N1 13 (52) 10 (40) 9 (34.6) 14 (58.3)
Number of metastatic LNs 0.020 0.049
<2 15 (62.5) 21 (91.3) 22 (88) 14 (63.6)
≥2 9 (37.5) 2 (8.7) 3 (12) 8 (36.4)
LN ratio 0.09±0.13 0.04±0.08 0.149 0.03±0.05 0.1±0.14 0.020
Differentiation 0.421 0.798
Well 4 (16) 7 (28) 6 (23.1) 5 (20.8)
Moderate 17 (68) 17 (68) 17 (65.4) 17 (70.8)
Poor 3 (12) 1 (4) 2 (7.7) 2 (8.3)
Undifferentiation 1 (4) 0� 1 (3.8) 0�
Lymphovascular invasion 0.752 0.374
No 18 (75) 16 (69.6) 18 (78.3) 16 (66.7)
Yes 6 (25) 7 (30.4) 5 (21.7) 8 (33.3)
Perineural invasion 0.387 0.882
No 14 (58.3) 10 (43.5) 12 (52.2) 12 (50)
Yes 10 (41.7) 13 (56.5) 11 (47.8) 12 (50)
NCCN, National Comprehensive Cancer Network; LNs, lymph nodes.
Values are presented as mean±standard deviation or n (%).
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Yonsei criteria (p=0.022) were significantly associated with a 
high Foxp3+/CD8+ ratio. Among the postoperative pathologic 
factors, having more than two of metastatic LNs was also relat-
ed to low CD8+ levels (p=0.020) and high Foxp3+/CD8+ ratio 
(p=0.049) (Table 3). In multivariate analysis, high levels of 
CA19-9 and not satisfying Yonsei criteria were associated with a 
high Foxp3+/CD8+ ratio [Exp(β)=3.558; 95% CI: 1.000–12.658; 
p=0.050] (Table 4). These two factors are preoperatively detect-
able clinical parameters. When we analyzed the survival out-
comes between the patients with low and high CD8+ T cells 
and low and high FOXP3+/CD8+ T cells ratios in each subgroup 
of patients according to metastatic LN (<2 and ≥2) and CA19-
9 (≤109 and >109), as well as Yonsei criteria (satisfying versus 
not satisfying), even the number of patients and the number 
of events in each group were too small to find meaningful re-
sults in all subgroups with Kaplan-Meier method, high CD8+ 
T cell and low FOXP3+/CD8+ T cell ratio were significantly as-
sociated with better survival in the subgroup with CA19-9 
>109 (p=0.022 and p=0.022, respectively). Also, high CD8+ T 
cell levels and a low FOXP3+/CD8+ T cell ratio had marginal 
significance in the metastatic LN <2 subgroup (p=0.055 and 
p=0.069, respectively) (Supplementary Figs. 1, 2, and 3, only 
online).
Several clinicopathologic factors that can predict the prog-
nosis of PDAC have been analyzed in various studies.1,24 Mul-
tivariate analysis in this study showed that more than two met-
astatic LNs [Exp(β)=3.354; 95% CI: 1.582–7.110; p=0.002] and 
intraoperative transfusion [Exp(β)=2.615; 95% CI: 1.248–5.482; 
p=0.011] were independent risk factors for DFS. Not satisfying 
Yonsei criteria [Exp(β)=2.590; 95% CI: 1.151–5.829; p=0.021] and 
more than two metastatic LNs [Exp(β)=2.536; 95% CI: 1.083– 
5.936; p=0.032] were also independent risk factors for OS (Ta-
ble 1). 
Slidell, et al.24 investigated the impact of nodal stage and 
LNRs affecting survival outcomes in a large population-based 
(with Surveillance, Epidemiology, and End Results, SEER data) 
study of patients with PDAC. In their study, N1 disease was 
associated with a worse 5-year survival rate, compared with N0 
disease (4.3% vs. 11.3%, respectively, p<0.001). For N1 patients, 
LNR was one of the most powerful factors associated with 
survival (LNR >0–0.2, 15 months; LNR >0.2–0.4, 12 months; 
LNR >0.4, 10 months) (p<0.001). We did not find differences 
in survival outcomes according to pathologic nodal stage or 
LNR in N1 stage in this study; however, having more than two 
metastatic LNs was an independent risk factor for DFS and OS 
(Table 1). 
Intraoperative transfusion has been shown to have an ad-
verse oncologic impact on various kinds of tumors, including 
PDAC.25-28 Although the actual mechanism by which intraop-
erative transfusion negatively affects survival outcomes is un-
known, it is thought to be an important factor in patient im-
mune system suppression.29 
Recently, although the number of patients diagnosed with 
early staged PDAC has increased due to routine medical check-
up, it is still difficult to diagnose PDAC early, which is associat-
ed with a good prognosis. Furthermore, it is not easy to clearly 
define what is truly an early staged PDAC. The preoperative 
resectability definition of the National Comprehensive Cancer 
Network (NCCN) guidelines,30 which are based on imaging 
studies, are the most widely used method for determining 
surgical or non-surgical treatment strategies for PDAC. How-
ever, even in the NCCN guideline for ‘resectable’ status, it is 
difficult to distinguish early stage PDAC. In the present study, 
we were unable to discern any differences in survival outcomes 
according to NCCN guidelines. In our previous studies,17-19 we 
found that the Yonsei criteria for left-sided PDAC, 1) tumor con-
fined to the pancreas, 2) intact fascia layer between the distal 
pancreas and the left adrenal gland and kidney, and 3) tumor 
located more than 1–2 cm from the celiac axis, were valuable 
selection criteria for surgeons seeking to apply minimally in-
vasive distal pancreatectomy. In the present study, patients 
that satisfied the Yonsei criteria showed favorable survival out-
comes in regards to DFS (p=0.021) and OS (p=0.001) (Table 1, 
Fig. 4) and were significantly associated with favorable TIL 
subset distributions. Although we merely noted an association 
between preoperatively detectable parameters and host im-
mune status against tumor, there are some reports20,31,32 that 
Table 4. Multivariate Analysis of Clinicopathologic Factors Affecting 
Foxp3+/CD8+ Ratio
Foxp3+/CD8+ (high vs. low)
Exp(β) 95% CI p value
CA19-9 (≥109  vs. <109), U/mL 3.558 1.000–12.658 0.050
















Combined factors 0.102 0.024
Satisfying Yonsei criteria+Ca19-9<109   8 (33.3) 5 (20) 11 (42.3) 2 (8.7)
Satisfying Yonsei criteria+CA19-9≥109   3 (12.5) 7 (28)   5 (19.2)   5 (21.7)
Not satisfying Yonsei criteria+CA19-9<109   3 (12.5) 8 (32)   6 (23.1)   5 (21.7)
Not satisfying Yonsei criteria+CA19-9≥109 10 (41.7) 5 (20)   4 (15.4) 11 (47.8)
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suggest that patients with a high density of TILs (CD3+, CD4+, 
and CD8+ T cells) in pancreatic cancer have a better prognosis 
than those who have a low density of TILs. Accordingly, fur-
ther well-designed translational research is warrant to better 
determine the biologic mechanisms for this phenomenon.
In conclusion, the host immune response against tumors 
plays a critical role in survival outcomes. High levels of tumor 
infiltrating CD8+ T cells and low Foxp3+/CD8+ ratios were sig-
nificantly associated with long DFS and OS in this study. The 
Yonsei criteria can play a role as clinically detectable biologic 
marker with which to predict tumor-immunologic status and 
survival outcomes of patients with resected left-sided PDAC.
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